Applied Genetic Technologies (AGTC)

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company that develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials, and achromatopsia that is also in Phase 1/2 clinical trials. The company is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology, a preclinical program in dry age-related macular degeneration, and two preclinical programs targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with the University of Florida, Bionic Sight, Inc., and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.